Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
heparinkalcium 5 000 enheter/0,2 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
heparinkalcium 12 500 enheter/0,5 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
tinzaparinnatrium 10 000 enheter/0,5 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
tinzaparinnatrium 14 000 enheter/0,7 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
tinzaparinnatrium 18 000 enheter/0,9 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
naloxonhydroklorid 400 mikrogram/ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
naloxonhydroklorid 800 mikrogram/2 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
peginterferon alfa-2a 135 mikrogram/0,5 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
triamcinolonacetonid 80 mg/2 ml, injektionsvätska, suspension, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
lidokainhydroklorid 100 mg/10ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
teriparatid 750 mikrogram/3 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
adrenalin 300 mikrogram/0,3 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
humant insulin (som glargininsulin) 300 enheter/3 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
humant insulin (som humant lösligt insulin) 300 enheter/3 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
humant insulin (som humant isofaninsulin) 300 enheter/3 ml, injektionsvätska, suspension, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
apomorfinhydroklorid 30 mg/3 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
lisproinsulin 300 enheter/3 ml, injektionsvätska, lösning, spruta |
Has unit of presentation |
False |
Syringe |
Inferred relationship |
Some |
|
Product containing precisely leuprorelin acetate 3.75 milligram/1 syringe powder for conventional release suspension for injection (clinical drug) |
Has unit of presentation |
True |
Syringe |
Inferred relationship |
Some |
|
Product containing precisely leuprorelin acetate 3.75 milligram/1 syringe powder for conventional release suspension for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Syringe |
Inferred relationship |
Some |
1 |
Leuprorelin acetate 7.5 mg powder for suspension for injection syringe |
Has unit of presentation |
True |
Syringe |
Inferred relationship |
Some |
|
Leuprorelin acetate 7.5 mg powder for suspension for injection syringe |
Has presentation strength denominator unit (attribute) |
True |
Syringe |
Inferred relationship |
Some |
1 |
Product containing precisely leuprorelin acetate 45 milligram/1 syringe powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Syringe |
Inferred relationship |
Some |
|
Product containing precisely leuprorelin acetate 45 milligram/1 syringe powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Syringe |
Inferred relationship |
Some |
1 |
Product containing precisely leuprorelin acetate 11.25 milligram/1 syringe powder for prolonged-release suspension for injection (clinical drug) |
Has unit of presentation |
True |
Syringe |
Inferred relationship |
Some |
|
Product containing precisely leuprorelin acetate 11.25 milligram/1 syringe powder for prolonged-release suspension for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Syringe |
Inferred relationship |
Some |
1 |
Product containing precisely leuprorelin acetate 30 milligram/1 syringe powder for prolonged-release suspension for injection (clinical drug) |
Has unit of presentation |
True |
Syringe |
Inferred relationship |
Some |
|
Product containing precisely leuprorelin acetate 30 milligram/1 syringe powder for prolonged-release suspension for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Syringe |
Inferred relationship |
Some |
1 |